Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Gastrointestinal 2Dermatologic 2Thoracic 1Other hematologic neoplasm 1Gynecologic 1Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 394Precursor Cell Lymphoblastic Leukemia-Lymphoma 226Hematologic Neoplasms 206Leukemia, Lymphocytic, Chronic, B-Cell 175Myelodysplastic Syndromes 144Leukemia 125Lymphoma 90Lymphoma, Non-Hodgkin 76Multiple Myeloma 67Leukemia, Myelogenous, Chronic, BCR-ABL Positive 67Recurrence 55Neoplasms 53Leukemia, Myelomonocytic, Chronic 50Burkitt Lymphoma 44Lymphoma, Large B-Cell, Diffuse 41Leukemia, Biphenotypic, Acute 41Myeloproliferative Disorders 39Lymphoma, Mantle-Cell 39Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 37Hodgkin Disease 36Lymphoma, B-Cell 32Lymphoma, Follicular 31Leukemia, B-Cell 27Lymphoma, B-Cell, Marginal Zone 24Anemia, Refractory, with Excess of Blasts 24Waldenstrom Macroglobulinemia 23Primary Myelofibrosis 21Myelodysplastic-Myeloproliferative Diseases 20Hematologic Diseases 19Lymphoma, T-Cell 16

Interventions

cabozantinib 1Specimen Handling 1Platinum Compounds 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colitis, Ulcerative × Other hematologic neoplasm × 90 days × Clear all
NCT03816345 2026-05-13

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

National Cancer Institute (NCI)

Phase 1 Recruiting
300 enrolled
Other hematologic neoplasm

Arthritis, Rheumatoid, Autoimmune Diseases, Colitis, Ulcerative, Crohn Disease, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Psoriasis, Scleroderma, Systemic, Sjogren's Syndrome, Inflammatory Bowel Diseases, Arthritis, Psoriatic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡